Drug resistant tuberculosis in Africa: Current status, gaps and opportunities
- PMID: 30568900
- PMCID: PMC6295755
- DOI: 10.4102/ajlm.v7i2.781
Drug resistant tuberculosis in Africa: Current status, gaps and opportunities
Abstract
Background: The World Health Organization End TB Strategy targets for 2035 are ambitious and drug resistant tuberculosis is an important barrier, particularly in Africa, home to over a billion people.
Objective: We sought to review the current status of drug resistant tuberculosis in Africa and highlight key areas requiring improvement.
Methods: Available data from 2016 World Health Organization global tuberculosis database were extracted and analysed using descriptive statistics.
Results: The true burden of drug resistant tuberculosis on the continent is poorly described with only 51% of countries having a formal survey completed. In the absence of this data, modelled estimates were used and reported 92 629 drug resistant tuberculosis cases with 42% of these occurring in just two countries: Nigeria and South Africa. Of the cases estimated, the majority of patients (70%) were not notified, representing 'missed cases'. Mortality among patients with multi-drug resistant tuberculosis was 21%, and was 43% among those with extensively drug resistant tuberculosis. Policies on the adoption of new diagnostic tools was poor and implementation was lacking. A rifampicin result was available for less than 10% of tuberculosis cases in 23 of 47 countries. Second-line drug resistance testing was available in only 60% of countries. The introduction of the short multi-drug resistant tuberculosis regimen was a welcome development, with 40% of countries having implemented it in 2016. Bedaquiline has also been introduced in several countries.
Conclusion: Drug resistant tuberculosis is largely missed in Africa and this threatens prospects to achieve the 2035 targets. Urgent efforts are required to confirm the true burden of drug resistant tuberculosis in Africa. Adoption of new tools and drugs is essential if the 2035 targets are to be met.
Conflict of interest statement
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Figures
Similar articles
-
[Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease].Mikrobiyol Bul. 2011 Jan;45(1):181-95. Mikrobiyol Bul. 2011. PMID: 21341173 Review. Turkish.
-
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11. Lancet Respir Med. 2018. PMID: 30001994
-
Molecular epidemiology of drug resistant Mycobacterium tuberculosis in Africa: a systematic review.BMC Infect Dis. 2020 May 13;20(1):344. doi: 10.1186/s12879-020-05031-5. BMC Infect Dis. 2020. PMID: 32404119 Free PMC article.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.Kekkaku. 2010 Jan;85(1):9-16. Kekkaku. 2010. PMID: 20143671
Cited by
-
Recurrent pneumothorax in a human immunodeficiency virus-positive patient with multidrug-resistant tuberculosis: a rare case of bronchopleural fistula: a case report.J Med Case Rep. 2022 May 31;16(1):214. doi: 10.1186/s13256-022-03436-1. J Med Case Rep. 2022. PMID: 35637524 Free PMC article.
-
Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana.Pathogens. 2019 Oct 28;8(4):208. doi: 10.3390/pathogens8040208. Pathogens. 2019. PMID: 31661825 Free PMC article.
-
Prevalence of Drug-Resistant Tuberculosis in Sudan: A Systematic Review and Meta-Analysis.Antibiotics (Basel). 2021 Jul 31;10(8):932. doi: 10.3390/antibiotics10080932. Antibiotics (Basel). 2021. PMID: 34438982 Free PMC article.
-
Sensitivity and specificity of the mean corpuscular volume and CD4/CD8 ratio in discriminating between rifampicin resistant and rifampicin sensitive tuberculosis.J Clin Tuberc Other Mycobact Dis. 2020 Nov 23;21:100205. doi: 10.1016/j.jctube.2020.100205. eCollection 2020 Dec. J Clin Tuberc Other Mycobact Dis. 2020. PMID: 33294630 Free PMC article.
-
Determinants of Multidrug-Resistant Mycobacterium tuberculosis Infection: A Multicenter Study from Southern Ethiopia.Infect Drug Resist. 2022 Jul 5;15:3523-3535. doi: 10.2147/IDR.S363628. eCollection 2022. Infect Drug Resist. 2022. PMID: 35818450 Free PMC article.
References
-
- WHO Global TB report. 2016. [cited 2018 January 22]. Available from: http://www.who.int/tb/publications/global_report/gtbr2016_executive_summ...
-
- WHO WHO END TB strategy. 2015. [cited 2018 January 22]. Available from: http://www.who.int/tb/End_TB_brochure.pdf?ua=1
-
- WHO Global TB report. 2017. [cited 2018 August 27]. Available from: http://www.who.int/tb/publications/global_report/gtbr2016_executive_summ...
-
- Abdool Karim SS, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: An urgent need to escalate the public health response. Lancet. 2009;374(9693):921–933. https://doi.org/10.1016/S0140-6736(09)60916-8 - DOI - PMC - PubMed
-
- Harries AD, Hargreaves NJ, Kemp J, et al. . Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet. 2001;357(9267):1519–1523. https://doi.org/10.1016/S0140-6736(00)04639-0 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous